FDA Affirms Exclusivity Period For Shire ADHD Drug

The U.S. Food and Drug Administration has affirmed its decision to grant a five-year new chemical entity exclusivity period to Shire PLC for its attention deficit hyperactivity disorder drug Vyvanse following...

Already a subscriber? Click here to view full article